New patent for the drug Boehringer Ingelheim OFEV – DrugPatentWatch
Annual Drug Patent Expiration for OFEV
Ofev is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from a single supplier. There are five patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for OFEV.
This drug has two hundred and fourteen patent family members in fifty one countries.
The generic ingredient in OFEV is nintedanib esylate. One registered supplier for this compound. Additional details are available on nintedanib esylate’s profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Make Better Decisions with DrugPatentWatch
» Start Your Free Trial Today «
Copyright © DrugPatentWatch. Originally published in New patent for the Boehringer Ingelheim drug OFEV
